Let's hear it from a more valuable source to you
" In vitro, data
suggests that Sotrovimab retained activity against variants of interest and concern (VOC),
including the alpha, beta, gamma, delta, and lambda variants. With the rapid emergence of VOC
Sotrovimab may be the preferred monoclonal antibody. "
https://covid19criticalcare.com/wp-content/uploads/2022/01/FLCCC-Protocols-A-Guide-to-the-Management-of-COVID-01-20-2022-FINAL.pdf